Xtampza ER offers an oxycodone formulation in previously unavailable administration options1,2
- Administration Options
- Options for Swallowing Difficulties
Xtampza ER may be administered in any of the following ways:
1. Xtampza ER [prescribing information]. Canton, MA: Collegium Pharmaceutical, Inc; 2016. 2. OxyContin [prescribing information]. Stamford, CT: Purdue Pharma L.P.; 2015.
Flexible administration options for patients with swallowing difficulties
Maintains ER properties when sprinkled on soft foods3,4,5
- Xtampza ER can be sprinkled on soft foods including applesauce, pudding, yogurt, ice cream, or jam
Similar drug release with gastrostomy/nasogastric administration5
1. Xtampza ER [prescribing information]. Canton, MA: Collegium Pharmaceutical, Inc; 2016. 2. OxyContin [prescribing information]. Stamford, CT: Purdue Pharma L.P.; 2015. 3. Kopecky EA, Fleming AB, Noonan PK, et al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. J Opioid Manag. 2014;10:233-246. 4. Kopecky EA, O’Connor M, Marseilles A, Varanasi RK, Fleming AB. Poster presented at PAINWeek; September 2015; Las Vegas, NV. 5. US Food and Drug Administration. Advisory committee briefing document: Xtampza ER. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm461640.pdf. Published September 11, 2015. Accessed May 11, 2016. 6. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Size, shape, and other physical attributes of generic tablets and capsules: guidance for industry. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm377938.pdf. Published June, 2015. Accessed September 1, 2015.